LRRK2 Inhibitors as Promising Treatment for Parkinson’s Disease
ACS Chemical Neuroscience · 2024
DOI: 10.1021/acschemneuro.4c00657 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Chemical Neuroscience, 2024. Verfasst von Shuoyan Tan und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Parkinson Disease, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 8 Literaturangaben. Gefördert von: Fundo para o Desenvolvimento das Ci?ncias e da Tecnologia.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- State Key Laboratory of Chinese Medicine Modernization, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China.
- Faculty of Applied Sciences, Macao Polytechnic University, Macao 999078, China.
ORCID-Profile: Huanxiang Liu, Xiaojun Yao
Förderung
- Fundo para o Desenvolvimento das Ci?ncias e da Tecnologia
Zitieren
APA
Tan, S., Liu, H., & Yao, X. (2024). LRRK2 Inhibitors as Promising Treatment for Parkinson’s Disease. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.4c00657
Vancouver
Tan S, Liu H, Yao X. LRRK2 Inhibitors as Promising Treatment for Parkinson’s Disease. ACS Chemical Neuroscience. 2024. doi:10.1021/acschemneuro.4c00657
BibTeX
@article{Tan2024,
author = {Tan, Shuoyan and Liu, Huanxiang and Yao, Xiaojun},
title = {LRRK2 Inhibitors as Promising Treatment for Parkinson’s Disease},
journal = {ACS Chemical Neuroscience},
year = {2024},
doi = {10.1021/acschemneuro.4c00657}
}
EUVIMED